Renalytix Ai, Inc.
Clinical trials sponsored by Renalytix Ai, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Blood test could flag rapid kidney failure risk in diabetes Results expected Nov 2026 (estimated)
- Blood test may predict kidney decline in diabetes — a large trial investigates Results expected Dec 2026 (estimated)
-
Blood test could predict who faces rapid kidney decline in diabetes
Diagnosis OngoingThis trial tests whether a blood-based test called KidneyIntelX can help doctors better manage patients with type 2 diabetes and early-stage chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this te…
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Blood test could flag rapid kidney failure risk in diabetes
Diagnosis OngoingThis trial is testing whether a diagnostic test called KidneyIntelX can help doctors better manage patients with type 2 diabetes and early-stage chronic kidney disease. The test predicts the risk of rapid kidney function decline over five years. Researchers will see if using this…
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Blood test may predict rapid kidney decline in diabetes
Diagnosis OngoingThis trial tests whether a blood-based test called KidneyIntelX can help doctors better manage type 2 diabetes patients with early to moderate chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this …
Sponsor: Renalytix AI, Inc. • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC